16 research outputs found

    Preparation of the C-ribose-labeled 2′--TOM protected ribonucleoside phosphoramidites –

    No full text
    <p><b>Copyright information:</b></p><p>Taken from "Short, synthetic and selectively C-labeled RNA sequences for the NMR structure determination of protein–RNA complexes"</p><p>Nucleic Acids Research 2006;34(11):e79-e79.</p><p>Published online 28 Jun 2006</p><p>PMCID:PMC1904103.</p><p>© 2006 The Author(s)</p> Abbreviations: Ac = acetyl, Bz = benzoyl, Ibu = isobutyryl, CE = cyanoethyl, DMT = (4,4′-dimethoxy)trityl, TOM = (triisopropylsilyl)oxymethyl. Reagents and conditions: () Adapted from Saito (), detailed procedure in Supplementary Data: 1. FeCl, MgSO, acetone, 20°; 2. pyridinium dichromate, AcO, CHCl, reflux; 3. HIO, THF, 20°; 4. NaBH, THF/EtOH 1:1, 20°; 5. BzCl, pyridine, 20°; 6. AcO, AcOH, HSO, 20°. () 6-Chloro--isobutyrylpurine-2-amine, ,-bis(trimethylsilyl)acetamide (BSA), MeSiOTf, 1,2-dichloroethane, 65°. () 1. Allyl alcohol, DABCO, DBU, 20°; 2. NaOH, THF/MeOH/HO, 0°; 3. DMT-Cl, pyridine, 20°. () Pd(PhP), HNEt, PPh, CHCl, 20°. () Synthesis of : 1. -benzoyladenine, BSA, SnCl, 1,2-dichloroethane, 65°; 2. NaOH, THF/MeOH/HO, 0°; 3. DMT-Cl, pyridine, 20°; synthesis of : 1. uracil, BSA, MeSiOTf, MeCN, 60°; 2. MeNH, EtOH, 20°; 3. DMT-Cl, pyridine, 20°. () BuSnCl, PrNEt, TOM-Cl, 1,2-dichloroethane, 80° according to (). () 1. AcO, DMAP, pyridine 25°; 2. 4-chlorophenyl phosphorodichloridate, 1-1,2,4-triazole, PrNEt, MeCN, 4° → 20°; 3. aqueous NH, dioxane/MeCN, 20°; 4. NaOH, THF/MeOH/HO, 4° 5. AcO, DMF, 20°, according to (). () 2-Cyanoethyldiisopropylphosphoramidochloridite, PrNEt, CHCl, 20°, according to ()

    Bredia hirsuta Bl.

    No full text
    原著和名: ハシカンボク科名: ノボタン科 = Melastomataceae採集地: 鹿児島県 屋久島 屋久町 安房〜上屋久町 小杉谷 (大隅 屋久島 安房〜小杉谷)採集日: 1964/8/18採集者: 萩庭丈壽整理番号: JH045335国立科学博物館整理番号: TNS-VS-99533

    Linum virginianum L.

    No full text
    原著和名: キバナノマツバニンジン科名: アマ科 = Linaceae採集地: 千葉県 千葉市 千葉大学構内 (下総 千葉市 千葉大学構内)採集日: 1976/8/9採集者: 萩庭丈壽整理番号: JH045221国立科学博物館整理番号: TNS-VS-99522

    Basic principles of the ABI Method.

    No full text
    <p>Scheme of the imaging system used for the acquisition of phase-contrast tomographic data. A monochromatic X-ray beam impinges on the sample. After its interaction with matter the refracted beam is filtered by the analyzer crystal before reaching the detection system. The whole setup used in the study measures around 3 m.</p

    Clinical mammography and sonography of patient B.

    No full text
    <p>In-vivo mammography in mediolateral oblique projection before (A), after 4 cycles NAC (B) and after completion of NAC (C). Ultrasound before NAC (D). Tumor indicated by arrowheads. Please note the excessive calcifications (white spots in A–D) within the tumor. The exact tumor borders are not visible in mammography and sonography.</p

    Clinical mammography, sonography and MRI of patient A.

    No full text
    <p>In-vivo mammography of patient A in craniocaudal (A and C) and mediolateral oblique (B and D) projection before (A and B) and after completion of NAC (C and D). Ultrasound before NAC (E). In-vivo MRI including contrast-enhanced T1 weighted gradient-echo sequence after manual injection of 30 ml gadopentetate dimeglumine (Magnevist <sup>®</sup> 0.5 mmol/ml) (F) and the corresponding first subtraction image after 2 min (G) in an axial view using a dedicated sensitivity-encoding enabled bilateral breast coil with a 1.5-Tesla system. The tumor is marked with arrowheads. Please note that the tumor is only partially imaged in conventional mammography due to the prepectoral position (A–D) and in Ultrasound (E) due to the extensive size.</p

    Measurement of pure Solutrast contrast agent.

    No full text
    <p>Grey value scaling is given in brackets. The first column shows the same image with the tube filled with water for three different contrast modalities: (a) transmission [0, 0.9], (d) differential phase [</p><p></p><p></p><p><mo>−</mo></p><p><mi>π</mi><mn>2</mn></p><p></p><p></p><p></p>, <p></p><p></p><p></p><p><mi>π</mi><mn>2</mn></p><p></p><p></p><p></p>], (g) dark field [0, 1.0]. The second columns shows the same image with the tube filled with pure Solutrast in three different modalities: (b) transmission [0, 0.9], (e) differential phase [<p></p><p></p><p><mo>−</mo></p><p><mi>π</mi><mn>2</mn></p><p></p><p></p><p></p>, <p></p><p></p><p></p><p><mi>π</mi><mn>2</mn></p><p></p><p></p><p></p>], (h) dark field [0, 1.0]. The third column shows the subtraction of the image with contrast agent (second column) from the image with water (first column) for three different contrast modalities: (c) transmission [0, 0.2], (f) differential phase [<p></p><p></p><p><mo>−</mo></p><p><mi>π</mi><mn>2</mn></p><p></p><p></p><p></p>, <p></p><p></p><p></p><p><mi>π</mi><mn>2</mn></p><p></p><p></p><p></p>], (i) dark field [0, 0.13].<p></p

    Dark-field signal subtraction and multimodal images.

    No full text
    <p>Left column: dark-field signal subtraction images. Right column: threshold-limited, filtered superimposition of the dark-field subtraction image (in color) on the respective original transmission image (grey values range: [0, 0.9]). (a)-(b) 100% PVA microbubbles suspension, (c)-(d) 10% PVA microbubbles suspension, (e)-(f) 1.3% PVA microbubbles suspension.</p
    corecore